LivaNova Valuation
Is L2IV34 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Share Price vs Fair Value
What is the Fair Price of L2IV34 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for L2IV34?
Other financial metrics that can be useful for relative valuation.
| What is L2IV34's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | US$2.85b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 2.7x |
| Enterprise Value/EBITDA | 21.6x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does L2IV34's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 1.5x | ||
ODPV3 Odontoprev | 2.6x | 4.5% | R$6.2b |
FLRY3 Fleury | 1.1x | 7.2% | R$7.7b |
HAPV3 Hapvida Participações e Investimentos | 1x | 7.8% | R$28.1b |
NVST Envista Holdings | 1.2x | 2.9% | US$3.0b |
L2IV34 LivaNova | 2.4x | 4.6% | R$2.8b |
Price to Earnings Ratio vs Industry
How does L2IV34's PE Ratio compare vs other companies in the Global Medical Equipment Industry?
Price to Sales Ratio vs Fair Ratio
What is L2IV34's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 2.4x |
| Fair PS Ratio | n/a |
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?